Skip to main content

Advertisement

Table 1 Cumulative reduction in cases (percent) of HPV 6/11/16/18 disease by HPV vaccination over time in Estonia, model estimates

From: The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia

  Over 25 years Over 50 years Over 100 years
HPV16/18-related cervical cancer 31 (2%) 654 (17%) 4103 (52%)
HPV16/18-related CIN2/3 1390 (12%) 9541 (40%) 32508 (68%)
HPV16/18-related CIN1 554 (15%) 3391 (45%) 10760 (71%)
HPV6/11-related CIN1 271 (32%) 1016 (61%) 2591 (77%)
HPV6/11-related genital warts (female) 6663 (36%) 23246 (63%) 58035 (79%)
HPV6/11-related genital warts (male) 2092 (28%) 7873 (53%) 20047 (67%)
  1. * Percentages rounded to nearest 1; ** Cases rounded to nearest 1.